Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This Phase 3 study is designed to investigate the safety, diagnostic performance, and
clinical usefulness of the imaging agent Gleolan (aminolevulinic acid hydrochloride, also
referred to as ALA HCl, ALA, 5-ALA), an orally administered imaging agent for the real-time
detection and visualization of de novo or recurrent epithelial ovarian cancer during tumor
debulking.